Testing for Personalized Care
Cancer Testing Options: Cost vs. Comprehensiveness
Interactive visualization comparing testing scope, cost, and insurance coverage
Germline DNA Testing
Insurance Coverage:
Always
Sometimes
Never
Evidence Level:
High
Medium
Low
Secondary Analysis Potential
Key Insights
- • Comprehensive Genome-Wide tests provide maximum data for ongoing secondary analysis
- • Multi-modal tests (CARIS, EXACTA, OncoExTra, Tempus) appear across multiple charts, offering cost-effective comprehensive profiling
- • Secondary analysis markers (dashed borders) indicate tests that collect more data than they report
- • Tempus platform advantages: xT CDx provides matched normal genome data; xR enables comprehensive transcriptome analysis
- • Expression comprehensive tests enable secondary analyses like tumor subtyping, specific gene signatures, and custom prediction algorithms from raw transcriptomic data
- • Large-panel ctDNA tests (523+ markers) support secondary clonal evolution analysis to track tumor genetic changes over time
- • Signatera monitoring patients receive full exome sequencing of normal and tumor tissue at no additional charge, providing extensive secondary analysis opportunities
- • Insurance coverage varies significantly - always check with your provider
- • Evidence levels help identify the most clinically validated options
***Make sure to click on each test in the figure for a pop-up with more information.
Click here for a full searchable and downloadable table and an explanation on the different data types:
Sign up for an Educational and Q&A Session
- Understand the testing landscape - Learn about available approaches from basic biomarkers to sophisticated multi-omics analysis
- Evaluate any testing option for your situation - Get a framework to assess scope, evidence, and value of different tests
- Navigate the research-clinical gap - Understand why advanced testing approaches often aren't routinely offered and how to bridge that gap
- Advocate effectively with your medical team - Learn how to ask informed questions and have productive conversations about enhanced testing options
- Access comprehensive resources - Get detailed comparison tables and tools to support your decision-making
If none of these times work for you, please provide your availability and we will consider scheduling an additional time slot
The reality: Most patients only learn about basic testing approaches and standard of care, while sophisticated analysis options and targeted treatments remain undiscussed
ER
PR
H2
Ki
Single Biomarkers
Individual protein measurements
→
21-70 genes
Gene Panels
Limited gene signatures
→
20K+ genes
Comprehensive Genomics
Whole genome analysis
→
DNA
RNA
Protein
Metabol
Multi-Omics
Integrated molecular layers
→
AI Multimodal
Genomics + imaging + AI analysis
One key CEtHI objective is to bridge the gap between
what we know in research and
what we do in the clinic.
As a genetic epidemiologist, I am in position to help patients navigate the full spectrum
of testing options and leverage comprehensive molecular data for informed decision-making.
what we know in research and
what we do in the clinic.
As a genetic epidemiologist, I am in position to help patients navigate the full spectrum
of testing options and leverage comprehensive molecular data for informed decision-making.
Patient Empowerment. Patient Dignity. Patient Flourishing.
